Biosimilars are starting to make a significant impact in overall drug spending, which is what they are designed to do, said Scott Soefje, PharmD, director of pharmacy cancer care at Mayo Clinic.
Scott Soefje, PharmD, director of pharmacy cancer care at Mayo Clinic, explains how interchangeable biosimilars are important—especially on the pharmacy benefit side—and serve as another step toward treating biosimilars like generic drugs.
Transcript
What is the predicted global drug spending by 2027?
It's estimated that by around 2027, the total global expenditures will be somewhere around $1.5 trillion. Oncology is probably going to be somewhere around $300 billion of that, and it's estimated that biosimilars will be somewhere in that 15% to maybe 20% range as far as total amount of the oncology biologics. I think it's gonna be a little hard to put an exact figure on what we're going to project by 2027 because some of it depends on uptake, how things change, what new ones come out between now and then. But they're starting to make a significant impact in the overall cost of drugs and that's what they're designed to do.
Why is the interchangeability designation so important for insulin biosimilars, like Rezvoglar and Semglee, for patients with diabetes?
Interchangeability is an interesting concept, and I think it's going to be more important for those drugs that are dispensed through retail pharmacies than they have been for the biosimilars, so far, that have been dispensed in infusion centers. In my institution and in a lot of institutions, we declare biosimilars therapeutically equivalent, and we have the ability to just change them out as we see fit. When you start getting into the retail setting, pharmacists don't have that authority unless they have a collaborative practice agreement with the provider. Interchangeability gives the pharmacist the choice to say, "This is the cheaper drug, this is the one we need, so let's go choose that one." So I think these interchangeables, particularly on the pharmacy benefit side, are going to be very, very important.
[There are] a whole lot of complexities that go along with them, because payers are making a lot of demands, formulary demands. What if the one you choose is not on the formulary? All of those kind of complicated things are going to get in there. But I do think that these new interchangeables are the first step to get us to the point where, from a policy perspective, we start treating biosimilars like generic drugs.
New Insights Into Meth-Associated PAH Care Gaps: Anjali Vaidya, MD, on Closing the Divide
June 4th 2025Research from Anjali Vaidya, MD, FACC, FASE, FACP, Temple University Hospital, reveals critical care gaps for patients with methamphetamine-associated pulmonary arterial hypertension (PAH), emphasizing the need for early diagnosis and integrated support.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
Tailored Dosing for MM Matters More Than Drug Count: Ajai Chari, MD
April 25th 2025When it comes to treating multiple myeloma (MM), Ajai Chari, MD, argued that more is not always better. More intense treatment regimens, or those with more drugs, don't necessarily guarantee better outcomes.
Read More